½ÃÀ庸°í¼­
»óǰÄÚµå
1594477

½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå : ÅëÁõ À¯Çü, ÀûÀÀÁõ, Ä¡·á¹ý, À¯Åë ä³Î, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Neuropathy Pain Treatment Market by Pain Type, Indication, Treatment, Distribution Channel, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀº 2023³â 77¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 85¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 11.53% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 166¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½Å°æº´Áõ¼º ÅëÁõ Ä¡·á¿¡´Â ´ç´¢º´, È­Çпä¹ý, ½ÅüÀû ¼Õ»ó µî ´Ù¾çÇÑ ¿øÀο¡ ÀÇÇÑ ½Å°æ ¼Õ»óÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ½Å°æº´Áõ¼º ÅëÁõ¿¡ ¼ö¹ÝµÇ´Â ºÒÆíÇÔÀ» ¿ÏÈ­Çϱâ À§ÇÑ Ä¡·á¹ý ¹× ¾à¹°ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Ä¡·áÀÇ Çʿ伺Àº ½Å°æº´Áõ¼º ÅëÁõÀÇ ¸¸¼ºÀûÀÌ°í ¼è¾àÇØÁö±â ½¬¿î Ư¼ºÀ¸·Î ÀÎÇØ »îÀÇ Áú¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í È¿°úÀûÀÎ °ü¸® Àü·«ÀÌ ÇÊ¿äÇÏ´Ù´Â Á¡¿¡¼­ ´õ¿í °­Á¶µË´Ï´Ù. ½Å°æº´Áõ¼º ÅëÁõ Ä¡·áÀÇ Àû¿ë ¹üÀ§´Â ÀǾàǰ, ÀÇ·á±â±â, ħ¼ú ¹× »ýȰ½À°ü °³¼±°ú °°Àº ´ëü ¿ä¹ý¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â º´¿ø, ¿Ü·¡ Áø·á¼Ò µî ÀÇ·á ½Ã¼³ ¿Ü¿¡µµ ÆíÀǼºÀ» Ãß±¸ÇÏ´Â ¸¸¼ºÁúȯ ȯÀÚ¸¦ À§ÇÑ ÀçÅà ġ·á ȯ°æÀ» ÁÖ·Î Æ÷ÇÔÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 77¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 85¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 166¾ï 1,000¸¸ ´Þ·¯
CAGR(%) 11.53%

½ÃÀå ¼ºÀåÀº ´ç´¢º´°ú ¾ÏÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ÀÇ Áõ°¡, ½Å°æº´Áõ¼º Áúȯ°ú Ä¡·á¹ý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Å©°Ô ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀü°ú »õ·Î¿î ÅëÁõ °ü¸® ÀåÄ¡ÀÇ °³¹ßÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, °³ÀÎÈ­µÈ ÀÇ·á¿Í ÀΰøÁö´ÉÀÇ ÅëÇÕÀ¸·Î ´õ ³ªÀº Áø´Ü°ú Ä¡·áÀÇ °³ÀÎÈ­¸¦ ÅëÇØ ȯÀÚ °á°ú¸¦ Å©°Ô °³¼±ÇÒ ¼ö ÀÖ´Â ±âȸ°¡ ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ³ôÀº °³¹ß ºñ¿ë, ±î´Ù·Î¿î ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ½Å°æº´Áõ Ä¡·áÁ¦ÀÇ Àå±â »ç¿ëÀ¸·Î ÀÎÇÑ ºÎÀÛ¿ë À§Çè µîÀÇ ¹®Á¦·Î ÀÎÇØ ½ÃÀå °³Ã´ÀÌ ½±Áö ¾ÊÀº »óȲÀÔ´Ï´Ù.

ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀº Áßµ¶¼ºÀÌ ¾ø°í È¿°úÀûÀÎ ÁøÅëÁ¦¸¦ °³¹ßÇÏ°í ½Å°æº´Áõ¼º Àå¾ÖÀÇ ¹ßº´°ú ÁøÇàÀ» ¿¹¹æÇÏ´Â ½Å°æ º¸È£Á¦¸¦ ã´Â µ¥ ÁßÁ¡À» µÎ¾î¾ß ÇÕ´Ï´Ù. ½Å°æÀμº ÅëÁõÀÇ À¯ÀüÀû ±â¹Ý¿¡ ´ëÇÑ ¿¬±¸µµ Ç¥Àû Ä¡·áÀÇ µ¹ÆÄ±¸¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀº Ä¡¿­Çϸç, Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú ¿¬±¸°³¹ß ÅõÀÚ°¡ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ½Å¾à°³¹ßÀ» À§ÇØ ¿¬±¸±â°ü°úÀÇ Á¦ÈÞ ¹× °øµ¿¿¬±¸¸¦ ¿ì¼±½ÃÇϰí, ÁøÈ­ÇÏ´Â ¼ö¿ä¿¡ È¿À²ÀûÀ¸·Î ´ëÀÀÇϱâ À§ÇØ È¯ÀÚ Áß½ÉÀÇ Á¦Ç° °³¹ß¿¡ Èû¾²´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® ÆÄ¾Ç

½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ½Å°æº´Áõ¼º ÅëÁõ Àα¸ Áõ°¡
    • Àü ¼¼°è ÀÇ·áºñ ÁöÃâ Áõ°¡
    • ½Å°æº´Áõ¼º ÅëÁõ ¿ÏÈ­Á¦ ¹× ½ÃÆÇ Á¦Ç° Áõ°¡
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • »ç¿ë °¡´ÉÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎÁöµµ°¡ ³·½À´Ï´Ù.
  • ½ÃÀå ±âȸ
    • »õ·Î¿î ÅëÁõ Ä¡·á¹ý ¼Ò°³
    • ¿ÏÈ­ÀÇ·á¿¡ ÃÊÁ¡À» ¸ÂÃá ÇÁ·Î±×·¥ ¹× ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå °úÁ¦
    • ȯÀÚÀÇ ½Å°æº´Áõ¼º ÅëÁõ¿¡ ÀûÇÕÇÑ Ä¡·á¹ýÀ» ã¾Æ³»´Â °ÍÀÇ º¹À⼺

Porter's Five Forces : ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀÇ °æÀï »óȲ ÆÄ¾Ç

½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå¿¡¼­ÀÇ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå ÅëÁõ Á¾·ùº°

  • ¹Ì°ñÅë
  • ±³¾×¼º ½Å°æÀå¾Ö
  • ´Ù¸® ÅëÁõ
  • ¸»ÃʽŰ溴Áõ
  • ȯÁö½Å°æÁõ
  • ´ë»óÆ÷Áø ÈÄ ½Å°æÅë(PHN)
  • ¿Ü»ó ÈÄ ½Å°æÀå¾Ö
  • »ïÂ÷½Å°æÅë

Á¦7Àå ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå : ÀûÀÀÁõº°

  • È­Çпä¹ý À¯¹ß¼º ¸»ÃʽŰ溴Áõ
  • ´ç´¢º´¼º ½Å°æº´Áõ
  • ôÃß°ü ÇùÂøÁõ

Á¦8Àå ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå : Ä¡·áº°

  • ¾à¹°
    • Ç׿ì¿ïÁ¦ Á¾·ù
      • ¼¼·ÎÅä´Ñ ³ë¸£¾Æµå·¹³¯¸°
      • »ïȯ°è Ç׿ì¿ïÁ¦
    • ¾à Á¾·ù
    • ¸ÖƼ¸ð´Þ Å×¶óÇÇ
    • NSAIDs À¯Çü
      • À̺ÎÇÁ·ÎÆæ
      • ³ªÇÁ·Ï¼¾
  • Ä¡·á

Á¦9Àå ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹¡¤µå·°½ºÅä¾î

Á¦10Àå ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Ŭ¸®´Ð
  • º´¿ø

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½Å°æº´Áõ¼º ÅëÁõ Ä¡·á ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦14Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Assertio Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
ksm 24.11.28

The Neuropathy Pain Treatment Market was valued at USD 7.74 billion in 2023, expected to reach USD 8.59 billion in 2024, and is projected to grow at a CAGR of 11.53%, to USD 16.61 billion by 2030.

Neuropathy pain treatment encompasses therapies and medications aimed at alleviating the discomfort associated with neuropathic pain, a condition often resulting from nerve damage due to various causes like diabetes, chemotherapy, or physical injury. The necessity of such treatments is underscored by the chronic and debilitating nature of neuropathic pain, which can significantly impact quality of life and necessitates effective management strategies. The application scope of neuropathy pain treatment spans across pharmaceuticals, medical devices, and alternative therapies such as acupuncture and lifestyle modifications. End-use predominantly involves healthcare facilities like hospitals and outpatient clinics, alongside home care settings for chronic sufferers seeking convenience.

KEY MARKET STATISTICS
Base Year [2023] USD 7.74 billion
Estimated Year [2024] USD 8.59 billion
Forecast Year [2030] USD 16.61 billion
CAGR (%) 11.53%

The market's growth is largely propelled by the increasing prevalence of diabetes and cancer, rising geriatric population, and the escalating awareness about neuropathic conditions and available treatments. Technological advancements in drug delivery systems and the development of novel pain management devices further fuel market expansion. Moreover, there are opportunities in personalized medicine and the integration of artificial intelligence for better diagnosis and treatment personalization, which can significantly elevate patient outcomes. Nonetheless, market growth is challenged by factors like high drug development costs, stringent regulatory approvals, and the risk of side effects associated with long-term usage of neuropathic medications.

Innovation in this sector should focus on developing non-addictive and more effective analgesics, as well as exploring neuroprotective agents that can prevent the onset or progression of neuropathic damage. Researching the genetic basis of neuropathic pain could also lead to breakthroughs in targeted therapy. The nature of the neuropathy pain treatment market is highly competitive, driven by continuous innovation and R&D investments. Companies are recommended to prioritize partnerships and collaborations with research institutions to advance drug discovery and to engage in patient-centric product development to meet evolving demands efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuropathy Pain Treatment Market

The Neuropathy Pain Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in neuropathic pain among population
    • Increasing global healthcare expenditure
    • Growing number of neuropathic pain relievers and over-the-counter products
  • Market Restraints
    • Limited awareness of available treatment options
  • Market Opportunities
    • Introduction of novel pain treatment alternatives
    • Programs and initiatives focusing on palliative care
  • Market Challenges
    • Complexity in identifying the treatment suitable for neuropathic pains in a patient

Porter's Five Forces: A Strategic Tool for Navigating the Neuropathy Pain Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuropathy Pain Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuropathy Pain Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuropathy Pain Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuropathy Pain Treatment Market

A detailed market share analysis in the Neuropathy Pain Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuropathy Pain Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuropathy Pain Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuropathy Pain Treatment Market

A strategic analysis of the Neuropathy Pain Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuropathy Pain Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson and Johnson Services, Inc., Novartis AG, Pfizer Inc., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Neuropathy Pain Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Pain Type, market is studied across Coccydynia, Entrapment Neuropathy, Foot Pain, Peripheral Neuropathy, Phantom Limb Neuropathy, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, and Trigeminal Neuralgia.
  • Based on Indication, market is studied across Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Spinal Stenosis.
  • Based on Treatment, market is studied across Drugs and Therapy. The Drugs is further studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
  • Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in neuropathic pain among population
      • 5.1.1.2. Increasing global healthcare expenditure
      • 5.1.1.3. Growing number of neuropathic pain relievers and over-the-counter products
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness of available treatment options
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel pain treatment alternatives
      • 5.1.3.2. Programs and initiatives focusing on palliative care
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in identifying the treatment suitable for neuropathic pains in a patient
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuropathy Pain Treatment Market, by Pain Type

  • 6.1. Introduction
  • 6.2. Coccydynia
  • 6.3. Entrapment Neuropathy
  • 6.4. Foot Pain
  • 6.5. Peripheral Neuropathy
  • 6.6. Phantom Limb Neuropathy
  • 6.7. Post Herpetic Neuralgia (PHN)
  • 6.8. Post Traumatic Neuropathy
  • 6.9. Trigeminal Neuralgia

7. Neuropathy Pain Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Chemotherapy-Induced Peripheral Neuropathy
  • 7.3. Diabetic Neuropathy
  • 7.4. Spinal Stenosis

8. Neuropathy Pain Treatment Market, by Treatment

  • 8.1. Introduction
  • 8.2. Drugs
    • 8.2.1. Antidepressant Drugs Type
      • 8.2.1.1. Serotonin Noradrenaline
      • 8.2.1.2. Tricyclic Antidepressants
    • 8.2.2. Medication Type
    • 8.2.3. Multimodal Therapy
    • 8.2.4. NSAIDs Type
      • 8.2.4.1. Ibuprofen
      • 8.2.4.2. Naproxen
  • 8.3. Therapy

9. Neuropathy Pain Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies & Drug Stores

10. Neuropathy Pain Treatment Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals

11. Americas Neuropathy Pain Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Neuropathy Pain Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Neuropathy Pain Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Assertio Holdings, Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Limited
  • 6. Baxter International Inc.
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Company
  • 11. GlaxoSmithKline PLC
  • 12. Johnson and Johnson Services, Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sun Pharmaceutical Industries Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦